Literature DB >> 11790290

Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study.

Ernesto L Schiffrin1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790290     DOI: 10.1007/s11906-002-0051-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  5 in total

1.  Blood-pressure lowering for the secondary prevention of stroke.

Authors:  J A Staessen; J Wang
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

2.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

4.  Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review.

Authors:  F H Messerli; E Grossman; U Goldbourt
Journal:  JAMA       Date:  1998-06-17       Impact factor: 56.272

Review 5.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.